Phio Pharmaceuticals (PHIO) vs Palatin Technologies (PTN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Phio Pharmaceuticals (PHIO) has outperformed Palatin Technologies (PTN) over the past year, losing 41.4% versus a loss of 79.9%. Over five years, PTN leads with a -99.3% price change compared with -99.6% for PHIO. Palatin Technologies is the larger company by market cap ($8.2 million vs $7.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHIO | PTN |
|---|---|---|
| Share price | $0.656 | $4.58 |
| Market cap | $7.84M | $8.16M |
| 1-day change | -8.25% | -7.10% |
| YTD return | -37.52% | -70.22% |
| 1-year return | -41.43% | -79.93% |
| 5-year return | -99.56% | -99.35% |
| EPS (TTM) | $-1.21 | $-2.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $8.83M |
| Net income (latest FY) | $-8.70M | $-8.38M |
| Operating margin | — | -98.17% |
| Net margin | — | -94.88% |
| 52-week high | $1.88 | $31.00 |
| 52-week low | $0.6395 | $4.51 |
| Distance from 52-week high | -65.11% | -85.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +2034.15% | +1068.12% |
| Average volume | 106.09K | 71.93K |
| Shares outstanding | 11.95M | 1.78M |
| Employees | 6 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHIO has outperformed PTN by 38.5 percentage points over the past year.
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
PHIO vs PTN FAQ
Which is bigger, Phio Pharmaceuticals or Palatin Technologies?
Palatin Technologies (PTN) is larger, with a market capitalization of $8.16M compared with $7.84M for Phio Pharmaceuticals (PHIO).
Which stock has performed better over the past year, PHIO or PTN?
PHIO returned -41.43% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.
Are Phio Pharmaceuticals and Palatin Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.